放化疗引起的听力损失仍是头颈癌患者的一个主要担忧。
Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients.
作者信息
Schmitt Nicole C, Page Brandi R
机构信息
a Office of the Clinical Director , National Institute on Deafness and Other Communication Disorders, National Institutes of Health , Bethesda , MD , USA.
b Department of Otolaryngology - Head and Neck Surgery , Johns Hopkins University , Baltimore , MD , USA , and.
出版信息
Int J Audiol. 2018 Sep;57(sup4):S49-S54. doi: 10.1080/14992027.2017.1353710. Epub 2017 Jul 20.
OBJECTIVE
Review of the literature regarding hearing loss in patients with head and neck cancer treated with chemoradiation.
DESIGN
Studies in the literature are reviewed that pertain to hearing loss sustained in head and neck cancer patients receiving cisplatin-based chemoradiation. Personal observations noted while treating these patients are also detailed.
STUDY SAMPLE
PubMed was searched for pertinent articles regarding hearing loss in head and neck cancer patients receiving cisplatin chemotherapy and/or radiation.
RESULTS
Studies on the incidence and severity of hearing loss in head and neck cancer patients are limited, but those studies suggest that the risk of hearing loss is greater with higher-dose regimens.
CONCLUSIONS
Newer cisplatin chemotherapy regimens using lower, weekly doses may be associated with a lower incidence and severity of hearing loss; however, large prospective studies are needed. Such information will be paramount to effective pre-treatment counselling of head and neck cancer patients.
目的
回顾关于接受放化疗的头颈癌患者听力损失的文献。
设计
回顾文献中与接受基于顺铂的放化疗的头颈癌患者所遭受的听力损失相关的研究。同时详细阐述在治疗这些患者时的个人观察结果。
研究样本
在PubMed上搜索关于接受顺铂化疗和/或放疗的头颈癌患者听力损失的相关文章。
结果
关于头颈癌患者听力损失发生率和严重程度的研究有限，但这些研究表明，更高剂量方案导致听力损失的风险更大。
结论
使用较低的每周剂量的新型顺铂化疗方案可能与较低的听力损失发生率和严重程度相关；然而，需要进行大型前瞻性研究。此类信息对于对头颈癌患者进行有效的治疗前咨询至关重要。
Zotero 插件